Interferons in the Persistence, Pathogenesis, and Treatment of HIV Infection

Mark L. Francis, Monte S. Meltzer, Howard E. Gendelman

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Interferon (IFN) plays an important role in the treatment and pathogenesis of HIV disease. Recent studies show beneficial effects of IFNα in the treatment of HIV-associated Kaposi's Sarcoma and early HIV-infection. Moreover, cell culture studies support these beneficial effects. HIV infection of monocytes is blocked by IFNα administered at the time of viral challenge. The IFNα-treated cells show no evidence of HIV infection. Viral gene products produced in monocytes infected with HIV then treated with IFNα gradually decrease to baseline. Large quantities of proviral DNA are seen in the HIV-infected IFNα-treated cells with little evidence for viral transcription suggesting true microbiological latency. While most viral infections of cells result in IFN production, HIV is a notable exception. Indeed, HIV does not induce monocytes to produce IFNα and blocks its production following poly (I)·poly (c) stimulation. This allows HIV yet another mechanism to evade an important host antiviral response. Paradoxically, the appearance of IFN activity in sera of HIV-infected patients is associated with disease progression, not resolution. Recent observations showing that the interaction between HIV-infected monocytes and PBMC results in the production of IFNαs with reduced anti-HIV activity may help explain this paradox. Thus, IFNα plays an important but complex role in HIV disease. The elucidation of cellular factors that regulate the antiretroviral effects of IFNα may lead to the development of novel therapeutic strategies for HIV infection.

Original languageEnglish (US)
Pages (from-to)199-207
Number of pages9
JournalAIDS Research and Human Retroviruses
Volume8
Issue number2
DOIs
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

Interferons
HIV Infections
HIV
Monocytes
Therapeutics
Poly I
Kaposi's Sarcoma
Viral Proteins
Virus Diseases
Antiviral Agents
Disease Progression
Cell Culture Techniques
DNA

ASJC Scopus subject areas

  • Immunology
  • Infectious Diseases
  • Virology

Cite this

Interferons in the Persistence, Pathogenesis, and Treatment of HIV Infection. / Francis, Mark L.; Meltzer, Monte S.; Gendelman, Howard E.

In: AIDS Research and Human Retroviruses, Vol. 8, No. 2, 01.01.1992, p. 199-207.

Research output: Contribution to journalArticle

@article{b83b851f62d14431a29b4a6f1ac37fcd,
title = "Interferons in the Persistence, Pathogenesis, and Treatment of HIV Infection",
abstract = "Interferon (IFN) plays an important role in the treatment and pathogenesis of HIV disease. Recent studies show beneficial effects of IFNα in the treatment of HIV-associated Kaposi's Sarcoma and early HIV-infection. Moreover, cell culture studies support these beneficial effects. HIV infection of monocytes is blocked by IFNα administered at the time of viral challenge. The IFNα-treated cells show no evidence of HIV infection. Viral gene products produced in monocytes infected with HIV then treated with IFNα gradually decrease to baseline. Large quantities of proviral DNA are seen in the HIV-infected IFNα-treated cells with little evidence for viral transcription suggesting true microbiological latency. While most viral infections of cells result in IFN production, HIV is a notable exception. Indeed, HIV does not induce monocytes to produce IFNα and blocks its production following poly (I)·poly (c) stimulation. This allows HIV yet another mechanism to evade an important host antiviral response. Paradoxically, the appearance of IFN activity in sera of HIV-infected patients is associated with disease progression, not resolution. Recent observations showing that the interaction between HIV-infected monocytes and PBMC results in the production of IFNαs with reduced anti-HIV activity may help explain this paradox. Thus, IFNα plays an important but complex role in HIV disease. The elucidation of cellular factors that regulate the antiretroviral effects of IFNα may lead to the development of novel therapeutic strategies for HIV infection.",
author = "Francis, {Mark L.} and Meltzer, {Monte S.} and Gendelman, {Howard E.}",
year = "1992",
month = "1",
day = "1",
doi = "10.1089/aid.1992.8.199",
language = "English (US)",
volume = "8",
pages = "199--207",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Interferons in the Persistence, Pathogenesis, and Treatment of HIV Infection

AU - Francis, Mark L.

AU - Meltzer, Monte S.

AU - Gendelman, Howard E.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Interferon (IFN) plays an important role in the treatment and pathogenesis of HIV disease. Recent studies show beneficial effects of IFNα in the treatment of HIV-associated Kaposi's Sarcoma and early HIV-infection. Moreover, cell culture studies support these beneficial effects. HIV infection of monocytes is blocked by IFNα administered at the time of viral challenge. The IFNα-treated cells show no evidence of HIV infection. Viral gene products produced in monocytes infected with HIV then treated with IFNα gradually decrease to baseline. Large quantities of proviral DNA are seen in the HIV-infected IFNα-treated cells with little evidence for viral transcription suggesting true microbiological latency. While most viral infections of cells result in IFN production, HIV is a notable exception. Indeed, HIV does not induce monocytes to produce IFNα and blocks its production following poly (I)·poly (c) stimulation. This allows HIV yet another mechanism to evade an important host antiviral response. Paradoxically, the appearance of IFN activity in sera of HIV-infected patients is associated with disease progression, not resolution. Recent observations showing that the interaction between HIV-infected monocytes and PBMC results in the production of IFNαs with reduced anti-HIV activity may help explain this paradox. Thus, IFNα plays an important but complex role in HIV disease. The elucidation of cellular factors that regulate the antiretroviral effects of IFNα may lead to the development of novel therapeutic strategies for HIV infection.

AB - Interferon (IFN) plays an important role in the treatment and pathogenesis of HIV disease. Recent studies show beneficial effects of IFNα in the treatment of HIV-associated Kaposi's Sarcoma and early HIV-infection. Moreover, cell culture studies support these beneficial effects. HIV infection of monocytes is blocked by IFNα administered at the time of viral challenge. The IFNα-treated cells show no evidence of HIV infection. Viral gene products produced in monocytes infected with HIV then treated with IFNα gradually decrease to baseline. Large quantities of proviral DNA are seen in the HIV-infected IFNα-treated cells with little evidence for viral transcription suggesting true microbiological latency. While most viral infections of cells result in IFN production, HIV is a notable exception. Indeed, HIV does not induce monocytes to produce IFNα and blocks its production following poly (I)·poly (c) stimulation. This allows HIV yet another mechanism to evade an important host antiviral response. Paradoxically, the appearance of IFN activity in sera of HIV-infected patients is associated with disease progression, not resolution. Recent observations showing that the interaction between HIV-infected monocytes and PBMC results in the production of IFNαs with reduced anti-HIV activity may help explain this paradox. Thus, IFNα plays an important but complex role in HIV disease. The elucidation of cellular factors that regulate the antiretroviral effects of IFNα may lead to the development of novel therapeutic strategies for HIV infection.

UR - http://www.scopus.com/inward/record.url?scp=0026534643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026534643&partnerID=8YFLogxK

U2 - 10.1089/aid.1992.8.199

DO - 10.1089/aid.1992.8.199

M3 - Article

C2 - 1371692

AN - SCOPUS:0026534643

VL - 8

SP - 199

EP - 207

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 2

ER -